Nehmer v. United States Veterans' Administration

712 F. Supp. 1404, 1989 WL 52821
CourtDistrict Court, N.D. California
DecidedMay 15, 1989
DocketCiv. A. C 86-6160 TEH
StatusPublished
Cited by47 cases

This text of 712 F. Supp. 1404 (Nehmer v. United States Veterans' Administration) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Nehmer v. United States Veterans' Administration, 712 F. Supp. 1404, 1989 WL 52821 (N.D. Cal. 1989).

Opinion

ORDER

THELTON E. HENDERSON, District Judge.

This matter comes before the Court on cross-motions for summary judgment. After careful and extensive consideration of the parties’ lengthy briefs and oral arguments of counsel, the Court hereby grants summary judgment in part to plaintiffs and summary judgment in part to defendants. The Court finds that defendants failed to comply with the Veterans’ Dioxin and Radiation Exposure Compensation Standards Act, 38 U.S.C. § 354 note (hereinafter “Dioxin Act” or “Act”) by erroneously interpreting two provisions of the Act. As a result, a portion of the regulation promulgated by the VA and codified at 38 C.F.R. § 3.311 is invalid, and the Court remands this case to the Veterans Administration *1407 for further proceedings not inconsistent with this opinion.

I. Factual Background.

This lawsuit is another round in the conflict between Vietnam Veterans and the United States Government over Agent Orange, a chemical defoliant used by the United States Armed Forces in Vietnam during the 1960’s to clear dense jungle land. Many veterans believe that their exposure to the chemical dioxin (contained in Agent Orange) has caused them to contract several debilitating diseases, particularly soft tissue sarcoma (“STS”) (malignant tumors that form in muscle, fat, or fibrous connective tissue) and porphyria cutanea tarda (“PCT”) (deficiencies in liver enzymes). In the late 1970’s, veterans filed a class action lawsuit against the manufacturers of Dioxin and the United States to obtain compensation for their alleged injuries. In 1984, the manufacturers agreed to establish a $180 million fund to compensate class members. In Re Agent Orange Product Liability Litigation, 597 F.Supp. 740 (E.D.N.Y.1984) aff'd 818 F.2d 145 (2d Cir.1987). However, actions against the United States were dismissed; the Second Circuit applied the doctrine developed in Feres v. United States, 340 U.S. 135, 71 S.Ct. 153, 95 L.Ed. 152 (1950) to bar recovery for injuries suffered through military service. In Re Agent Orange Product Liability Litigation, 818 F.2d 194 (2d Cir.1987).

Veterans also pursued their claims against the United States in another forum: they sought disability compensation from the Veterans’ Administration, claiming that the diseases they incurred were caused by exposure to Agent Orange during military service in Vietnam. However, the VA has consistently taken the position that only one disease — chloracne, a skin condition— arises from exposure to Agent Orange. Accordingly, the VA has routinely denied compensation for veterans who allege that exposure to Agent Orange has caused diseases other than chloracne. As of October 1, 1983, 9170 veterans filed claims with disabilities that they allege were caused by Agent Orange; 7709 were denied compensation because the VA found that the claimed diseases were not service connected. House Report No. 98-592, reprinted in U.S.Code Cong. & Adm.News, 98th Cong. 2d Sess., 1984, at 4452.

In 1984, Congress enacted the Veterans’ Dioxin and Radiation Exposure Compensation Standards Act (Dioxin Act), 38 U.S.C. § 354 note. The Act was passed amidst veterans’ “concern[s] about possible long-term health effects of exposure to herbicides containing dioxin,” section 2(1), as well as “scientific and medical uncertainty” regarding the long-term health effects of Agent Orange exposure. Section 2(l). 1 The Act’s purpose is to ensure that disability compensation is provided to veterans “for all disabilities arising after [service in Vietnam] that are connected, based on sound scientific and medical evidence, to such service.” Section 3. 2

The Act dramatically alters the process governing Agent Orange disability claims. Rather than have the VA determine in individual adjudicatory proceedings whether a particular veteran’s claimed disease was caused by Agent Orange exposure, the Act authorizes the Administrator of the VA (“Administrator”) to conduct rulemaking to determine which diseases will be deemed service connected for all diseases claimed *1408 to be caused by Agent Orange exposure. 3

To achieve these purposes, the Act requires the VA to appoint an advisory committee composed of experts in dioxin, experts in epidemiology, and interested members of the public to review the pertinent literature on dioxin and submit periodic recommendations and evaluations to the Administrator. Section 6. 4 The Act also compels the Administrator to adopt regulations governing the evaluation of the scientific evidence. Id. at Section 5(b)(1)(A). Finally, after receiving the recommendations of the Advisory Committee and other members of the public, the Act requires the Administrator to promulgate a regulation identifying diseases to be deemed service connected, based on “sound scientific and medical evidence”. Section 5(b)(2)(A)(i).

The Advisory Committee was established on March 4, 1985. The committee included four lay members with a demonstrated interest in dioxin issues, three recognized specialists on the health effects of dioxin, and five scientists with expertise in epidemiology, three of whom also had extensive experience studying the effects of dioxin.

On April 22,1985, the Administrator published a proposed rule. 50 Fed.Reg. 15848. The rule sets forth five factors to govern evaluation of the scientific evidence. Id. The rule also proposes service-connection for only one disease — chloracne manifesting itself within three months of a veteran’s service. The proposed rule states that “[s]ound scientific and medical evidence does not support a causal association between dioxin exposure” and any other diseases. Id. at 15849-15850.

Also on April 22, 1985, the Advisory Committee met for the first time. The Committee received background information on the Act and scientific studies on the effects of Agent Orange exposure. At the second meeting on June 24-25, 1985, the Committee reviewed a number of studies on dioxin’s effects on human populations and received written comments on the proposed regulation. The Committee recommended that the Administrator adopt the five factor guidelines in the proposed rule and agreed with the VA that only chloracne should be deemed service-connected. The Committee transmitted its findings to the Administrator.

On August 26, 1984, the VA published a final regulation identical to the proposed rule. 3

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Clegg v. Collins
Federal Circuit, 2025
Constantine v. McDonough
Federal Circuit, 2024
Lopez v. McDonough
Federal Circuit, 2022
200512-87606
Board of Veterans' Appeals, 2021
Euzebio v. McDonough
989 F.3d 1305 (Federal Circuit, 2021)
Nehmer v. US Veterans Administ
N.D. California, 2020
ROSANNA PRUENT-STEVENS VS. TOMS RIVER TWP. (TAX COURT OF NEW JERSEY)
206 A.3d 417 (New Jersey Superior Court App Division, 2019)
Procopio v. Wilkie
913 F.3d 1371 (Federal Circuit, 2019)
180727-287
Board of Veterans' Appeals, 2018
Robinson v. Wilkie
905 F.3d 1353 (Federal Circuit, 2018)
16-60 885
Board of Veterans' Appeals, 2018
Haddock v. United States
Federal Claims, 2017
11-34 086
Board of Veterans' Appeals, 2016
99-13 421
Board of Veterans' Appeals, 2015
05-00 791
Board of Veterans' Appeals, 2012
Lawrence Delisio v. Eric K. Shinseki
25 Vet. App. 45 (Veterans Claims, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
712 F. Supp. 1404, 1989 WL 52821, Counsel Stack Legal Research, https://law.counselstack.com/opinion/nehmer-v-united-states-veterans-administration-cand-1989.